Your browser doesn't support javascript.
Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.
Gasser, Romain; Cloutier, Marc; Prévost, Jérémie; Fink, Corby; Ducas, Éric; Ding, Shilei; Dussault, Nathalie; Landry, Patricia; Tremblay, Tony; Laforce-Lavoie, Audrey; Lewin, Antoine; Beaudoin-Bussières, Guillaume; Laumaea, Annemarie; Medjahed, Halima; Larochelle, Catherine; Richard, Jonathan; Dekaban, Gregory A; Dikeakos, Jimmy D; Bazin, Renée; Finzi, Andrés.
  • Gasser R; Centre de recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
  • Cloutier M; Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada.
  • Prévost J; Centre de recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
  • Fink C; Biotherapeutics Research Laboratory, Robarts Research Institute, London, ON NGA 5B7, Canada; Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5B7, Canada.
  • Ducas É; Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada.
  • Ding S; Centre de recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
  • Dussault N; Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada.
  • Landry P; Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada.
  • Tremblay T; Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada.
  • Laforce-Lavoie A; Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada.
  • Lewin A; Héma-Québec, Affaires Médicales et Innovation, Montréal, QC H4R 2W7, Canada; Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
  • Beaudoin-Bussières G; Centre de recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
  • Laumaea A; Centre de recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
  • Medjahed H; Centre de recherche du CHUM, Montréal, QC H2X 0A9, Canada.
  • Larochelle C; Centre de recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada; Department of Neurosciences, University of Montreal, Montreal, QC H2X 0A9, Canada.
  • Richard J; Centre de recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
  • Dekaban GA; Biotherapeutics Research Laboratory, Robarts Research Institute, London, ON NGA 5B7, Canada; Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5B7, Canada.
  • Dikeakos JD; Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5B7, Canada.
  • Bazin R; Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada. Electronic address: renee.bazin@hema-quebec.qc.ca.
  • Finzi A; Centre de recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada. Electronic address: andres.finzi@um
Cell Rep ; 34(9): 108790, 2021 03 02.
Article in English | MEDLINE | ID: covidwho-1077816
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-19, is essential to help control the infection. The neutralization activity of plasma from patients with COVID-19 decreases rapidly during the first weeks after recovery. However, the specific role of each immunoglobulin isotype in the overall neutralizing capacity is still not well understood. In this study, we select plasma from a cohort of convalescent patients with COVID-19 and selectively deplete immunoglobulin A, M, or G before testing the remaining neutralizing capacity of the depleted plasma. We find that depletion of immunoglobulin M is associated with the most substantial loss of virus neutralization, followed by immunoglobulin G. This observation may help design efficient antibody-based COVID-19 therapies and may also explain the increased susceptibility to SARS-CoV-2 of autoimmune patients receiving therapies that impair the production of immunoglobulin M (IgM).
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin M / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Etiology study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: North America Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.108790

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin M / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Etiology study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: North America Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.108790